Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16763566 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Shahbazian D, et al. (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25, 2781-91 16763566
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S422-p - eIF4B (human)
Orthologous residues
eIF4B (human): S422‑p, eIF4B (mouse): S422‑p, eIF4B (rat): S422‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p70S6K (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, pharmacological activator of upstream enzyme, genetic knockout/knockin of upstream enzyme
KINASE p90RSK (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme, pharmacological activator of upstream enzyme, transfection of wild-type enzyme, transfection of inactive enzyme, transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
U0126 serum inhibit treatment-induced increase
rapamycin serum inhibit treatment-induced increase
U0126 rapamycin augment treatment-induced decrease
SB203580 serum no effect upon treatment-induced increase
JNK inhibitor I serum no effect upon treatment-induced increase JNK inhibitor II
insulin increase
rapamycin insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
serum increase
serum inhibit treatment-induced increase fmk (fluoromethylketone)
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
eIF3-alpha (human) Induces co-immunoprecipitation

S1147-p - eIF4G (human)
Orthologous residues
eIF4G (human): S1147‑p, eIF4G iso3 (human): S1107‑p, eIF4G iso8 (human): S1148‑p, eIF4G (mouse): S1149‑p, eIF4G iso2 (mouse): S1135‑p, eIF4G (rat): S1147‑p, eIF4G (rabbit): S950‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase
insulin increase

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase
insulin increase
U0126 insulin inhibit treatment-induced increase
serum increase
serum no effect upon treatment-induced increase fmk (fluoromethylketone)

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase
insulin increase
U0126 insulin inhibit treatment-induced increase
serum increase
serum no effect upon treatment-induced increase fmk (fluoromethylketone)

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase
insulin increase
U0126 insulin inhibit treatment-induced increase
serum increase
serum no effect upon treatment-induced increase fmk (fluoromethylketone)

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase
insulin increase
U0126 insulin inhibit treatment-induced increase
serum increase
serum no effect upon treatment-induced increase fmk (fluoromethylketone)

T412-p - p70S6K (human)
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
serum increase
serum no effect upon treatment-induced increase fmk (fluoromethylketone)

S380-p - p90RSK (human)
Orthologous residues
p90RSK (human): S380‑p, p90RSK iso2 (human): S389‑p, p90RSK (mouse): S369‑p, p90RSK iso3 (mouse): , p90RSK (rat): S380‑p, p90RSK (chicken): S398‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
serum inhibit treatment-induced increase fmk (fluoromethylketone)

S240-p - S6 (human)
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase
insulin increase

S244-p - S6 (human)
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase
insulin increase

S422-p - eIF4B (mouse)
Orthologous residues
eIF4B (human): S422‑p, eIF4B (mouse): S422‑p, eIF4B (rat): S422‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p90RSK (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, siRNA inhibition of enzyme, pharmacological activator of upstream enzyme, transfection of wild-type enzyme, transfection of inactive enzyme, transfection of constitutively active enzyme
KINASE p70S6K (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, pharmacological activator of upstream enzyme, genetic knockout/knockin of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase
insulin p70S6K (mouse) inhibit treatment-induced increase S6k1/2 -/-
serum increase
rapamycin serum inhibit treatment-induced increase
serum p70S6K (mouse) inhibit treatment-induced increase S6k1/2 -/-
serum increase
rapamycin serum inhibit treatment-induced increase
serum PDK1 (mouse) inhibit treatment-induced increase PDK1 -/-

T203-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
serum PDK1 (mouse) no effect upon treatment-induced increase PDK1 -/-

Y205-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
serum PDK1 (mouse) no effect upon treatment-induced increase PDK1 -/-

T183-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
serum PDK1 (mouse) no effect upon treatment-induced increase PDK1 -/-

Y185-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
serum PDK1 (mouse) no effect upon treatment-induced increase PDK1 -/-

T412-p - p70S6K (mouse)
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase
insulin p70S6K (mouse) inhibit treatment-induced increase S6k1/2 -/-
serum increase
rapamycin serum inhibit treatment-induced increase
serum p70S6K (mouse) inhibit treatment-induced increase S6k1/2 -/-
serum increase
rapamycin serum inhibit treatment-induced increase
serum PDK1 (mouse) inhibit treatment-induced increase PDK1 -/-

S235-p - S6 (mouse)
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase
insulin p70S6K (mouse) inhibit treatment-induced increase S6k1/2 -/-
serum increase
rapamycin serum inhibit treatment-induced increase
serum p70S6K (mouse) inhibit treatment-induced increase S6k1/2 -/-

S236-p - S6 (mouse)
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase
insulin p70S6K (mouse) inhibit treatment-induced increase S6k1/2 -/-
serum increase
rapamycin serum inhibit treatment-induced increase
serum p70S6K (mouse) inhibit treatment-induced increase S6k1/2 -/-

S240-p - S6 (mouse)
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
serum PDK1 (mouse) inhibit treatment-induced increase PDK1 -/-

S244-p - S6 (mouse)
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
serum PDK1 (mouse) inhibit treatment-induced increase PDK1 -/-


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.